 | Up a level |
Jump to: Journal Article
Number of items: 1.
Journal Article
Loibl, S., Reinisch, M., Denkert, C., Fasching, P. A., Seiler, S., Link, T., Hanusch, C., Bjelic-Radisic, V., Schneeweiss, A., Huober, J., Jackisch, C., Rhiem, K. E., Untch, M., Solbach, C., Blohmer, J-U., Buechele, T., Nekljudova, V. and Loi, S. (2022). A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)-GeparPiPPa. Ann. Oncol., 33 (7). S. S627 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041